1.Yi Mou, Shuai Wen, Xinxing Gao & Zheng-Yu Jiang, Proteolysistargeting chimeras: a kaledoscope of targeted protein degradation，Future Med. Chem. (2022) 14(3), 139–141
2.Yi Mou, Shuai Wen, Yu-Xiu Li, Xin-Xing Gao, Xin Zhang, Zheng-Yu Jiang*, Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors, European Journal of Medicinal Chemistry, 2020,202:112532.
3.Zhangjian Huang#, Yi Mou#, ,Xiaojun Xu, Di Zhao, Yisheng Lai, Yuwen Xu,Cen Chen, Ping Li, Sixun Peng, Jide Tian, and Yihua Zhang，Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy，J. Med. Chem. 2017, 60, 8847-8857（共同第一作者）
4.牟伊，宋雨，文帅，王燕，姜正羽，Nrf2抑制剂在肿瘤治疗中的研究进展，药学学报，2022, 57(2): 321 −330
5.牟伊, 文帅, 王燕, 姜正羽*,可控性蛋白降解靶向嵌合体（PROTACs）技术研究进展，药学学报，2023，58(08):2193-2202.
